<?xml version="1.0" encoding="UTF-8"?>
<p id="Par15">Historically the use of hyperimmune serum for treatment of EVD, but also other VHF cases, has been reported [
 <xref ref-type="bibr" rid="CR70">70</xref>â€“
 <xref ref-type="bibr" rid="CR72">72</xref>]. During the West Africa outbreak, the WHO also approved the use of hyperimmune serum for the treatment of patients, although reportedly not widely used [
 <xref ref-type="bibr" rid="CR73">73</xref>]. A limited clinical trial during the outbreak indicated the safety, acceptability and feasibility of treatment with hyperimmune sera [
 <xref ref-type="bibr" rid="CR74">74</xref>]. Van Griensven and co-authors [
 <xref ref-type="bibr" rid="CR74">74</xref>] also argued the scalability of such a product, particularly given the number of potential immune donors now available in Guinea, Liberia and Sierra Leone.
</p>
